Creo Medical Group (CREO) Share Price, News & Analysis

Company Overview

Creo Medical Group PLC, through its subsidiaries, researches, develops, manufactures, and sells medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with flexible, accurate, and highly controllable devices delivered through a flexible endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for flexible endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device designed for soft tissue ablation; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues. In addition, it provides endotherapy accessories comprising ScopeSnare, an energy-based polypectomy snares; ScopeSnare Cold, a cutting wire for use in endoscopically in the removal of diminutive, sessile and pedunculated polyps, and tissue from within the GI tract; ScopeClip, a single-use rotational and repositionable hemoclips; ScopeBite, a portfolio of biopsy forceps; ScopeGrasp, a portfolio of grasping forceps; and ScopeInject, an injection needle. Creo Medical Group PLC was founded in 2003 and is based in Chepstow, the United Kingdom.

Key Stats

• Today's Range: 15.70 to 16.50
• 50-Day Range: 16.25 to 32.50
• 52-Week Range: 15.70 to 50
• Volume: 479,621 shs
• Average Volume: 689,722 shs
• Market Capitalization: £58.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CREO Stock Analysis - Frequently Asked Questions

How have CREO shares performed this year?

Creo Medical Group's stock was trading at GBX 46 at the beginning of the year. Since then, CREO stock has decreased by 64.9% and is now trading at GBX 16.14.
View the best growth stocks for 2024 here.

How were Creo Medical Group's earnings last quarter?

Creo Medical Group PLC (LON:CREO) posted its earnings results on Wednesday, September, 23rd. The company reported ($6.00) earnings per share (EPS) for the quarter. Creo Medical Group had a negative trailing twelve-month return on equity of 38.49% and a negative net margin of 73.93%.

How do I buy shares of Creo Medical Group?

Shares of CREO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Creo Medical Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Creo Medical Group investors own include Aviva (AV), IQE (IQE), Lloyds Banking Group (LLOY), Barclays (BARC), BP (BP), BT Group (BT.A) and Coats Group (COA).

Company Calendar

• Last Earnings: 9/23/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: LON:CREO
• CUSIP: N/A
• CIK: N/A
• Web: creomedical.com
• Phone: +44-1291-606005
• Fax: N/A
• Employees: 279
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-22,400,000.00
• Net Margins: -73.93%
• Pretax Margin: N/A
• Return on Equity: -38.49%
• Return on Assets: -20.09%

Debt

• Debt-to-Equity Ratio: 29.96
• Current Ratio: 3.24
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: £30.30 million
• Price / Sales: 1.97
• Cash Flow: GBX 6.79 per share
• Price / Cash Flow: 2.43
• Book Value: GBX 13 per share
• Price / Book: 1.27

Miscellaneous

• Outstanding Shares: 361,780,000
• Free Float: N/A
• Market Cap: £59.69 million
• Optionable: Not Optionable
• Beta: 0.86